The Experts below are selected from a list of 9078 Experts worldwide ranked by ideXlab platform
Vito Ninfo - One of the best experts on this subject based on the ideXlab platform.
-
three cases of pancreatic serous cystadenoma and Endocrine tumour
Journal of Clinical Pathology, 2006Co-Authors: Stella Blandamura, A Parenti, Barbara Famengo, Alessandra Canesso, Paolo Moschino, Claudio Pasquali, Sara Pizzi, Vincenza Guzzardo, Vito NinfoAbstract:Aims: To report three cases of serous cystadenoma and Endocrine tumour in the same pancreas, to review the literature and to evaluate the clinicopathological features of the tumours. Cases: Three women (71, 57 and 31 years old) were admitted to hospital, two for diseases unrelated to the pancreas and the third for increasing obstructive jaundice in von Hippel-Lindau disease. Preoperative examination showed two distinct lesions in the first patient and only cystic lesions in the other two. Results: Histological examination of the pancreas showed one serous oligocystic adenoma associated with a benign, well-differentiated Endocrine tumour, one serous oligocystic adenoma associated with an Endocrine microadenoma, and a von Hippel-Lindau-related cystic neoplasm with a well-differentiated Endocrine Carcinoma. Conclusions: Serous cystadenoma associated with Endocrine tumour shows some clinicopathological differences with respect to the two tumours considered separately, and with respect to von Hippel-Lindau-related cases, although there is no convincing evidence at present to justify considering this association as a separate entity.
Joël Guigay - One of the best experts on this subject based on the ideXlab platform.
-
Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (≥10%) Well-Differentiated Endocrine Carcinoma Staging
The Journal of Clinical Endocrinology & Metabolism, 2011Co-Authors: Ronan Abgral, Sophie Leboulleux, Désirée Deandreis, Anne Auperin, Jean Lumbroso, Clarisse Dromain, Pierre Duvillard, Dominique Elias, Thierry De Baere, Joël GuigayAbstract:FDG-PET is more sensitive than somatostatin receptor scintigraphy for high Ki67 well-differentiated Endocrine Carcinoma staging.
-
performance of 18fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for high ki67 10 well differentiated Endocrine Carcinoma staging
The Journal of Clinical Endocrinology and Metabolism, 2011Co-Authors: Ronan Abgral, Sophie Leboulleux, Désirée Deandreis, Anne Auperin, Jean Lumbroso, Clarisse Dromain, Pierre Duvillard, Dominique Elias, Thierry De Baere, Joël GuigayAbstract:FDG-PET is more sensitive than somatostatin receptor scintigraphy for high Ki67 well-differentiated Endocrine Carcinoma staging.
-
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated Endocrine Carcinoma
Endocrine-Related Cancer, 2009Co-Authors: Cosimo Durante, Sophie Leboulleux, Jean Lumbroso, Clarisse Dromain, Dominique Elias, Thierry De Baere, Houda Boukheris, P. Duvillard, David Malka, Joël GuigayAbstract:Survival of metastatic gastroenteropancreatic well-differentiated Endocrine Carcinoma (GEP WDEC) is not well characterized. We evaluated the long-term outcome and prognostic factors for survival in 118 patients with distant metastases from GEP WDEC. Inclusion criteria were 1) pathological review by a single pathologist according to the present WHO criteria, 2) absence of previous therapy apart from surgery, 3) complete morphological evaluation within 3 months including somatostatin receptor scintigraphy, and 4) follow-up at Gustave-Roussy Institute until death or study's end. Clinical, biological marker, and pathological parameters were analyzed in univariate and multivariate statistical models. Survival after the first complete imaging work-up of the metastatic disease was determined using Kaplan-Meier method. Overall, survival for 5 years after the diagnosis of metastatic disease was 54%. In multivariate analysis, age (hazard ratio (HR): 1.05, 95% confidence interval (CI): 1.01-1.08, P = 0.01), the number of liver metastases (HR: 3.4, 95% CI: 1.4-8.3, P = 0.01), tumor slope (HR: 1.1, 95% CI: 1.0-1.1, P = 0.001), and initial surgery (HR: 0.3, 95% CI: 0.1-0.8, P = 0.01) were predictive of survival. Five-year survival was 100%, 91% (95% CI, 51-98%), 62% (95% CI, 37-83%), and 9% (95% CI, 6-32%) when patients had 0, 1, 2, 3 or more poor prognostic features respectively. This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials.
Chia-tung Shun - One of the best experts on this subject based on the ideXlab platform.
-
combined pancreatic Endocrine tumor and serous cystadenoma
Journal of the Formosan Medical Association, 2009Co-Authors: Minshu Hsieh, Yu-wen Tien, Chia-tung ShunAbstract:Pancreatic serous cystadenomas account for 1-2% of all exocrine pancreatic tumors, and Endocrine tumors account for 1-2% of all pancreatic neoplasms. The combination of pancreatic serous cystadenoma and Endocrine tumor is even rarer. Here, we report two cases of combined pancreatic serous adenoma and Endocrine tumor. One was a 64-year-old woman with serous cystadenoma and pancreatic Endocrine tumor. The other case was a 28-year-old woman with von Hippel-Lindau disease with combined pancreatic serous oligocystic adenoma and well-differentiated malignant Endocrine Carcinoma. Reviewing the literature, we found 15 similar cases that showed two different age distributions and clinical presentations. Careful examination of benign serous cystadenoma should be kept in mind during clinical practice, to rule out the possibility of combined malignant Endocrine tumor. In addition, von Hippel-Lindau disease should also be suspected when a young adult presents with combination of pancreatic serous cystadenoma and Endocrine tumor.
Clarisse Dromain - One of the best experts on this subject based on the ideXlab platform.
-
Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (≥10%) Well-Differentiated Endocrine Carcinoma Staging
The Journal of Clinical Endocrinology & Metabolism, 2011Co-Authors: Ronan Abgral, Sophie Leboulleux, Désirée Deandreis, Anne Auperin, Jean Lumbroso, Clarisse Dromain, Pierre Duvillard, Dominique Elias, Thierry De Baere, Joël GuigayAbstract:FDG-PET is more sensitive than somatostatin receptor scintigraphy for high Ki67 well-differentiated Endocrine Carcinoma staging.
-
performance of 18fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for high ki67 10 well differentiated Endocrine Carcinoma staging
The Journal of Clinical Endocrinology and Metabolism, 2011Co-Authors: Ronan Abgral, Sophie Leboulleux, Désirée Deandreis, Anne Auperin, Jean Lumbroso, Clarisse Dromain, Pierre Duvillard, Dominique Elias, Thierry De Baere, Joël GuigayAbstract:FDG-PET is more sensitive than somatostatin receptor scintigraphy for high Ki67 well-differentiated Endocrine Carcinoma staging.
-
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated Endocrine Carcinoma
Endocrine-Related Cancer, 2009Co-Authors: Cosimo Durante, Sophie Leboulleux, Jean Lumbroso, Clarisse Dromain, Dominique Elias, Thierry De Baere, Houda Boukheris, P. Duvillard, David Malka, Joël GuigayAbstract:Survival of metastatic gastroenteropancreatic well-differentiated Endocrine Carcinoma (GEP WDEC) is not well characterized. We evaluated the long-term outcome and prognostic factors for survival in 118 patients with distant metastases from GEP WDEC. Inclusion criteria were 1) pathological review by a single pathologist according to the present WHO criteria, 2) absence of previous therapy apart from surgery, 3) complete morphological evaluation within 3 months including somatostatin receptor scintigraphy, and 4) follow-up at Gustave-Roussy Institute until death or study's end. Clinical, biological marker, and pathological parameters were analyzed in univariate and multivariate statistical models. Survival after the first complete imaging work-up of the metastatic disease was determined using Kaplan-Meier method. Overall, survival for 5 years after the diagnosis of metastatic disease was 54%. In multivariate analysis, age (hazard ratio (HR): 1.05, 95% confidence interval (CI): 1.01-1.08, P = 0.01), the number of liver metastases (HR: 3.4, 95% CI: 1.4-8.3, P = 0.01), tumor slope (HR: 1.1, 95% CI: 1.0-1.1, P = 0.001), and initial surgery (HR: 0.3, 95% CI: 0.1-0.8, P = 0.01) were predictive of survival. Five-year survival was 100%, 91% (95% CI, 51-98%), 62% (95% CI, 37-83%), and 9% (95% CI, 6-32%) when patients had 0, 1, 2, 3 or more poor prognostic features respectively. This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials.
-
the doxorubicin streptozotocin combination for the treatment of advanced well differentiated pancreatic Endocrine Carcinoma a judicious option
European Journal of Cancer, 2004Co-Authors: Th Delaunoit, Clarisse Dromain, P. Duvillard, M. Ducreux, Valerie Boige, Jeanchristophe Sabourin, Martin Schlumberger, T De Baere, P Rougier, P RuffieAbstract:Abstract Due to their rarity, only few trials have studied the role of the doxorubicin-streptozotocin (DS) combination in advanced well-differentiated pancreatic Endocrine Carcinomas (AWDPEC). However, the published results are inconsistent. We reviewed all AWDPEC (5-year period, 45 patients) treated in our institution with the DS combination for: objective response rate (ORR), progression-free survival, overall survival (OS) and toxicity. An ORR of 36% (95% Confidence Interval (CI) 22–49) was obtained, with 16 partial responses (PR). The mean duration of PR was of 19.7 months. Two and 3-year OS rates were 50.2 and 24.4%, respectively. Toxicities were mainly digestive (grade ⩾3 vomiting, 13%) and haematological (grade ⩾3 neutropenia, 24%). Previous systemic chemotherapy and malignant hepatomegaly were associated with a poorer ORR ( P =0.033, P =0.016) and OS ( P =0.008, P =0.045). Multivariate analysis demonstrated previous chemotherapy as the only independent predictive-factor for survival ( P =0.013). In conclusion, our data confirm the sensitivity of AWDPEC to the DS combination, with an ORR of 36% and a remarkable median response duration of 19.7 months, and suggests that it could be considered as a valid option in first-line therapy.
Stella Blandamura - One of the best experts on this subject based on the ideXlab platform.
-
three cases of pancreatic serous cystadenoma and Endocrine tumour
Journal of Clinical Pathology, 2006Co-Authors: Stella Blandamura, A Parenti, Barbara Famengo, Alessandra Canesso, Paolo Moschino, Claudio Pasquali, Sara Pizzi, Vincenza Guzzardo, Vito NinfoAbstract:Aims: To report three cases of serous cystadenoma and Endocrine tumour in the same pancreas, to review the literature and to evaluate the clinicopathological features of the tumours. Cases: Three women (71, 57 and 31 years old) were admitted to hospital, two for diseases unrelated to the pancreas and the third for increasing obstructive jaundice in von Hippel-Lindau disease. Preoperative examination showed two distinct lesions in the first patient and only cystic lesions in the other two. Results: Histological examination of the pancreas showed one serous oligocystic adenoma associated with a benign, well-differentiated Endocrine tumour, one serous oligocystic adenoma associated with an Endocrine microadenoma, and a von Hippel-Lindau-related cystic neoplasm with a well-differentiated Endocrine Carcinoma. Conclusions: Serous cystadenoma associated with Endocrine tumour shows some clinicopathological differences with respect to the two tumours considered separately, and with respect to von Hippel-Lindau-related cases, although there is no convincing evidence at present to justify considering this association as a separate entity.